This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Many years ago, this article was focused on its title subject (as 99.9999% of encyclopedia articles are), noting that SNDRIs are a new frontier in psychopharmacology and that only a few are in clinical trials. Now it has transformed into an article encompassing every pharmacological class of medication. The entire purpose of having a separate article for a particular topic is to elucidate aspects that might come across as unnecessary detail when covering its broader, related/inclusive topic. If I knew nothing about psychopharmacology, I would be horribly confused after reading this. At best, this article is redundant; at worse, it is obfuscating the very subject it purports to clarify. This page, as of 2015 Dec 17, is unfit for publication and should be either revised or rewritten from scratch.Frostlark (talk) 17:31, 17 December 2015 (UTC)[reply]
This article was nominated for deletion on May 23, 2007. The result of the discussion was STUBIFY.
This was formerly a much longer article. This longer version may be found in the history.
This article is complete and utter garbage. It seems like it was written entirely by one person, and that person seems very biased, ignorant and pretentious. —Preceding unsigned comment added by 72.200.115.120 (talk) 07:15, 2 October 2009 (UTC)[reply]
I've re-written some of the article to remove irrelevant information and outdated clinical candidates. I've shrunk the size of the article significantly, however I think that perhaps adding more information about the three relevant neurotransmitters roles in depression would be useful. It also needs more citations. Comrinec (talk) 16:40, 6 June 2010 (UTC)[reply]
Still too large article for such a small class of substances which includes especially cocaine
Most of the substances mentioned in the article are not triple "Serotonin-norepinephrine-dopamine reuptake inhibitors" "SNDRI". The article makes a long review of many other classes which are not at all "SNDRI". It speaks about MAOI, SSRI, SNRI which all of them are not at all "SNDRI" and have no relevance to the item. The main and most known "SNDRI" is cocaine, which is a psychostimulant abuse substance and recreational drug, which causes a high and dangerous craving, compulsive drug seeking, associated with the activation of specific reward structures in the brain, with daily or binges abuse, often dependence, intoxications with potential agitation, anxiety. paranoia or agressiveness, discontinuation syndromes often with severe depression. The presence of SSRi, SNRI, and other antidepressive medications which are not "SNDRI", and are not abusable substance, only is producing confusion among the readers, confusion between pharmacological treatment and substance abuse.Ewan2 (talk) 21:43, 4 July 2014 (UTC)[reply]
The part about magic bullet pharmaceutical drugs which gives dimebon as an example of an expecially efficient drug is contrary to new research about this substance and is also contradictory to the Wikipedia article on dimebon. — Preceding unsigned comment added by 217.209.169.236 (talk) 12:56, 14 January 2017 (UTC)[reply]
